RT Journal Article SR Electronic T1 Screening and early warning system for chronic obstructive pulmonary disease with obstructive sleep apnoea based on the medical Internet of Things in three levels of healthcare: protocol for a prospective, multicentre, observational cohort study JF BMJ Open JO BMJ Open FD British Medical Journal Publishing Group SP e075257 DO 10.1136/bmjopen-2023-075257 VO 14 IS 2 A1 Pan, Zihan A1 Liao, Sha A1 Sun, Wanlu A1 Zhou, Haoyi A1 Lin, Shuo A1 Chen, Dian A1 Jiang, Simin A1 Long, Huanyu A1 Fan, Jing A1 Deng, Furong A1 Zhang, Wenlou A1 Chen, Baiqi A1 Wang, Junyi A1 Huang, Yongwei A1 Li, Jianxin A1 Chen, Yahong YR 2024 UL http://bmjopen.bmj.com/content/14/2/e075257.abstract AB Introduction Chronic obstructive pulmonary disease (COPD) and obstructive sleep apnoea (OSA) are prevalent respiratory diseases in China and impose significant burdens on the healthcare system. Moreover, the co-occurrence of COPD and OSA exacerbates clinical outcomes significantly. However, comprehensive epidemiological investigations in China remain scarce, and the defining characteristics of the population affected by COPD and OSA, alongside their intrinsic relationship, remain ambiguous.Methods and analysis We present a protocol for a prospective, multicentre, observational cohort study based on a digital health management platform across three different healthcare tiers in five sites among Chinese patients with COPD. The study aims to establish predicative models to identify OSA among patients with COPD and to predict the prognosis of overlap syndrome (OS) and acute exacerbations of COPD through the Internet of Things (IoT). Moreover, it aims to evaluate the feasibility, effectiveness and cost-effectiveness of IoT in managing chronic diseases within clinical settings. Participants will undergo baseline assessment, physical examination and nocturnal oxygen saturation measuring. Specific questionnaires screening for OSA will also be administered. Diagnostic lung function tests and polysomnography will be performed to confirm COPD and OSA, respectively. All patients will undergo scheduled follow-ups for 12 months to record the changes in symptoms, lung functions and quality of life. Primary outcomes include the prevalence and characteristics of OS, while secondary outcomes encompass OS prognosis and the feasibility of the management model in clinical contexts. A total of 682 patients with COPD will be recruited over 12–24 months.Ethics and dissemination The study has been approved by Peking University Third Hospital, and all study participants will provide written informed consent. Study results will be published in an appropriate journal and presented at national and international conferences, as well as relevant social media and various stakeholder engagement activities.Trial registration number NCT04833725.